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Received October 11, 2011; accepted July 22, 2012AbstractBackground: Rotational atherectomy (RA) has been advocated in the bare metal stent (BMS) era but is underused now due to technique demands
and nonsuperior outcomes. The aim of this study was to evaluate the procedural and clinical outcomes of patients with very complex, severely
calcified coronary lesions treated by RA and drug-eluting stents (DESs) in our current percutaneous coronary intervention (PCI) practice in
a region where RA use has been limited by lack of insurance reimbursement.
Methods: From March 2004 to November 2010, all consecutive patients who required RA treatment for severely calcified de novo lesions of
native coronary arteries followed by DES implantation were queried from the cath lab database and recruited. Their clinical and angiographic
characteristics at the index PCI were analyzed and completed by a thorough review of the medical charts.
Results: A total of 67 consecutive patients with 71 very complex, heavily calcified coronary lesions treated with RA plus DES were recruited. Of
these patients, 64% presented with acute coronary syndrome, 9.0% with cardiogenic shock, 43.3% with chronic renal failure, and 50.7% with
diabetes. Multiple-vessel diseases were found in 92.5% of our patients, and the average coronary artery calcification (CAC) score was 3.6 1.4.
Of the coronary lesions, 26.7% were either balloon-uncrossable or balloon-undilatable. The angiographic success rate was 100% with one non-Q
myocardial infarction. Five patients (7.5%) died in hospital, all initially presenting with extensive myocardial infarction and/or cardiogenic
shock. The out-of-hospital major adverse cardiac event was 17.9% at the mean follow-up of 23.2 months (range: 5e86), primarily due to high
target-lesion revascularization and target-vessel revascularization rates of 10.4% and 10.4%, respectively. Only one (1.5%) probable subacute
stent thrombosis was observed in the follow-up.
Conclusion: RA with DES implantation in very complex, heavily calcified coronary lesions can achieve very low complication and low out-of-
hospital major adverse cardiac event rates even in high-risk patients despite use limited by lack of insurance reimbursement. The study results
convince us to sustain and even broaden the use of this novel, but underused, device in the DES era.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Severely calcified coronary lesions, by virtue of their
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http://dx.doi.org/10.1016/j.jcma.2012.10.004pressures to eliminate the “waist” of the stenoses. Vessels
exposed to high inflation pressure had a significantly higher
incidence of mural thrombus, dissection, and medial necrosis.1
It is not unusual that calcified lesions cannot be crossed with
even the smallest available balloons. Very tight calcified
lesions may also resist dilatation even at the highest possible
balloon pressure or may cause rupture of the balloons at low
inflation pressure. Furthermore, stent delivery to calcified
lesions may be difficult and stent expansion suboptimal due tohinese Medical Association. All rights reserved.
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tomy (RA), with its ability to differentially ablate calcified
plaques, is particularly useful in these lesions.2,3 RA has been
advocated in the bare metal stents (BMSs) era. However, in the
published literature,4 it has often been underused due to
technical difficulty, cumbersome setup, and nonsuperior
outcomes. The ever-growing use of percutaneous coronary
interventions (PCIs) in calcified, chronically totally occluded
(CTO), complex, bifurcational, and left main lesions in recent
years may demand more procedural use of these ablation
devices.5e7 Drug-eluting stents (DESs) have been widely used
recently because of their consistent treatment benefits of
reducing restenosis and clinical events compared with BMS.8
DES also provided good follow-up results for a premature
coronary artery disease (CAD) group with multiple athero-
sclerotic risk factors.9 However, DESs face the same issues as
BMSs in calcified and resistant lesions. Up-to-date but limited
clinical data are available on the outcomes of RA in chal-
lenging heavily calcified coronary lesions in the DES era,
especially in the Chinese population.10 Therefore, it was
important to investigate the outcomes of RA plus DES in
a region where use of the device was not reimbursed by
insurance and frequently taken as the last resort for difficult-
to-treat lesions. The aim of this study was to evaluate the
procedural and clinical outcomes of patients with very
complex, severely calcified coronary lesions treated by RA
and DES in our current PCI practice.
2. Methods2.1. Patient populationA Windows 2000-based cardiac catheterization report
databank has been established at Taichung Veterans General
Hospital (TCVGH). It uses the hospital-information-system
data stored in the mainframe computer and contains all
angiographic reports over the past 15 years. From March 2004
to November 2010, all consecutive patients who required RA
treatment for severely calcified de novo lesions of native
coronary arteries followed immediately by DES implantation
were queried from the database for recruitment. All partici-
pants with interventions for restenotic lesions were excluded.
Patients were also excluded from the study if the RA was
followed by BMS placement or balloon angioplasty only. The
relevant clinical and angiographic data at the time of index
PCI were retrieved from the database and completed by
thorough review of the medical chart records. This study
protocol was approved by the Institutional Review Board for
Human Research and the ethics committee of TCVGH.2.2. Angiographic characterization and measurementsThe angiographic measurements were made on a viewing
workstation with software for quantitative analysis of angio-
grams (Medcon/Horizon/TCS, Tel Aviv, Israel). The angio-
graphic characteristics of target coronary lesions in the index
coronary angiogram were obtained by reviewing the sessioncine thoroughly. The CAD vessel numbers were defined as the
number of the three major coronary vessels that had a 70% or
greater stenotic diameter. Coronary artery calcification (CAC)
was defined as readily apparent radio-opacities within the
vascular walls on the cine before contrast medium injection.
The CAC score in the target lesion was measured by cine-
fluoroscopy at the time of diagnostic coronary angiography.
The angiographic scoring system was as follows: 0, none; 1,
blocky or spotty calcification; 2, linear calcification compro-
mising one side of the arterial lumen; 3, linear calcification
found unidirectionally compromising both sides of the arterial
lumen; 4, linear calcification found bidirectionally compro-
mising both sides of the arterial lumen; and 5, blanket/
circumferential and dense calcification.11
All PCIs were performed by experienced, qualified opera-
tors using standard practice at our cath lab. Patients were
pretreated with aspirin and clopidogrel, or a minimum of
300 mg loading dose of clopidogrel was administered if,
in rare cases, patients were not pretreated. Heparin was
administered to maintain an activated clotting time (ACT) of
> 300 seconds or about 200 seconds if a GP IIb/IIIA inhibitor
was used. Rotablation procedures started with a 1.25 or
1.5 mm burr at a speed of 180,000e200,000 rpm and were
mostly supplemented by another burr one size bigger. The PCI
then proceeded with balloon dilatation and DES implantation
to achieve minimal residual stenosis. Dual-antiplatelet therapy
with aspirin and clopidogrel (75 mg/day) was continued for at
least 12 months after DES implantation.
Angiographic success was defined as achievement of
a residual stenosis < 20% in the presence of Grade III
thrombolysis in myocardial infarction (TIMI) flow. The
procedural success was defined as achieving angiographic
success without in-hospital major adverse cardiac events
(MACEs), including all-cause death, myocardial infarction
(MI), and repeat revascularization. MI was defined according
to current guidelines.12 Target lesion revascularization (TLR)
was defined as a repeat revascularization for a restenosis >
50% in the target segment. Target vessel revascularization
(TVR) was defined as any repeat revascularization within the
treated vessel. Stent thrombosis was classified according to the
Academic Research Consortium (ARC) definition.132.3. Statistical analysisDescriptive analyses were used in this study. Continuous
variables were reported as mean standard deviation. Cate-
goric variables are presented as frequencies with percentage.
3. Results
During the study period, a total of 126 rotablations (2.4% of
all PCIs) were done (Fig. 1). Excluding procedures for native
or intrastent restenotic lesions and those not supplemented by
DES, a total of 67 patients with 71 severely calcified de novo
coronary lesions, which were successfully treated with RA
plus DES implantation, were recruited into this study and
retrospectively analyzed. The baseline clinical characteristics
Fig. 1. A typical case of heavily calcified coronary lesions at baseline (A and B) treated with rotablation (C) and post-drug-eluting stent implantation. (D) The
presence of circular and diffuse heavy calcification along the treated segment should preclude the proper balloon angioplasty and stent delivery and expansion.
Table 1
Baseline clinical characteristics (n¼ 67).
Age (y) 73.2 10.3
Male (N ), % 42 (62.7%)
Current or ex-smoker (N ), % 33 (49.3%)
Systemic hypertension (N ), % 58 (86.6%)
Hypercholesterolemia (N ), % 29 (43.3%)
Diabetes mellitus (N ), % 34 (50.7%)
Chronic renal failure (N ), % 29 (43.3%)
Prior MI (N ), % 17 (25.4%)
Prior CABG (N ), % 5 (7.5%)
Clinical presentation (N ), %
Stable angina 24 (35.8%)
Unstable angina 24 (35.8%)
NSTEMI 13 (19.4%)
STEMI 6 (9.0%)
Cardiogenic shock 6 (9.0%)
LVEF (%) 42.1 12.2
Total cholesterol (mg/dL) 162.5 39.2
LDL-cholesterol (mg/dL) 94.3 34.7
Creatinine (mg/dL) 2.1 2.1a
Plasma glucose (mg/dL) 130.8 51.2
Continuous variables are presented as numbers (%) or mean SD.
CABG¼ coronary artery bypass graft surgery; LDL = low-density lipoprotein;
MI¼myocardial infarction; NSTEMI¼ non-ST segment elevation MI; STE-
MI¼ ST segment elevation MI.
a Included six hemodialysis patients.
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patients was 73.2 10.3 years. Thirty-four (50.7%) patients
had diabetes mellitus and 29 (43.3%) chronic renal failure.
Five (7.5%) had prior coronary artery bypass graft surgery
(CABG), and 17 (25.4%) had prior myocardial infarction
(MI). Twenty-four (35.8%) patients presented with unstable
angina, 13 (19.4%) non-ST-elevation MI (NSTEMI) and six
(9.0%) ST-elevation MI (STEMI). Additionally, the average
serum creatinine was 2.1 2.1 mg/dL.
The angiographic success rate was 100% in these patients
in whom the rotablation burr could be delivered to the target
lesion and DES implantation completed, complicated by one
(1.5%) non-Q MI. There was no other major procedural
complication. The overall angiographic and procedural char-
acteristics of our patients are presented in Table 2. Sixty-two
(92.5%) of these patients had multiple-vessel diseases. The
number of diseased vessels per patient was 2.5 0.6. Most
lesions were located at the left anterior descending artery
(LAD) or right coronary artery (RCA) (76.0%) and 12 (16.9%)
were at the left main coronary artery (LM). There were six
(8.5%) chronic total occlusions and 28 (39.4%) bifurcation
lesions. Fourteen lesions (19.7%) were balloon-uncrossable
and five (7.0%) balloon-undilatable. The average CAC score
Table 2
Lesion and procedural characteristics (71 lesions in 67 patients).
CAD vessel numbers (n), %
Single-vessel disease 5 (7.5%)
DVD 25 (37.3%)
TCD 37 (55.2%)
Number of diseased vessels 2.5 0.6
Target vessel (n), %
Left main 12 (16.9%)
Left anterior descending artery 40 (56.3%)
Left circumflex artery 5 (7.0%)
Right coronary artery 14 (19.7%)
Chronic total occlusion (n), % 6 (8.5%)
Bifurcation lesion (n), % 28 (39.4%)
Balloon-uncrossable lesion (n), % 14 (19.7%)
Balloon-undilatable lesion (n), % 5 (7.0%)
CAC score 3.6 1.4
Reference vessel size (mm) 2.6 0.6
Lesion length (mm) 41.3 16.8
Baseline minimal lumen diameter (mm) 0.7 0.2
Baseline percent diameter stenosis (%) 75.5 5.8
Number of burrs used per patient (n) 1.6 0.4
Final burr size (mm) 1.6 0.2
Burr/artery ratio 0.6 0.1
DES implantation (n), % 71 (100%)
Multiple stenting (n), % 41 (57.7%)
Mean stent diameter (mm) 2.8 0.2
Total stent length per lesion (mm) 46.7 22.7
Total stent length per patient (mm) 63.6 32.1
Noncompliant balloon post dilatation (n), % 23 (32.4%)
Maximum balloon diameter (mm) 2.9 0.4
Maximum inflation pressure (atm) 15.3 3.9
Final minimal lumen diameter (mm) 2.4 0.4
Final percent diameter stenosis (%) 18.2 5.5
Values are presented as numbers (%) or mean standard deviation.
CAC¼ coronary artery calcification; CAD¼ coronary artery disease;
DES¼ drug-eluting stent; DVD¼ double vessel disease; TLR¼ target lesion
revascularization; TVR¼ target vessel revascularization; TVD¼ triple vessel
disease.
Table 3
MACE and stent thrombosis incidence (n¼ 67).
In-hospital MACE (n), % 5 (7.5%)
Death 5 (7.5%)
Q wave MI 0
Non-Q wave MI 1 (1.5%)
TLR 0
TVR 0
Out-of-hospital MACE (n), % 12 (17.9%)
Death 1 (1.5%)
Q wave MI 0
Non-Q wave MI 0
TLR 7 (10.4%)
TVR 7 (10.4%)
Stent thrombosis, any (n), % 1 (1.5%)
Definite 0
Probable 1 (1.5%)
Possible 0
Acute 0
Subacute 1 (1.5%)
Late 0
Very late 0
MACE¼major adverse cardiac event; MI¼myocardial infarction;
TLR¼ target lesion revascularization; TVR¼ target vessel revascularization.
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patient was 1.6 0.4. The final burr size was 1.6 0.2 mm
and the burr/artery ratio was 0.6 0.1. A Taxus stent (Boston
Scientific, Galway, Ireland) was implanted in 24 lesions,
Cypher stent (Cordis, Johnson and Johnson Company, Roden,
Netherlands) in 15, Endeavor Resolute stent (Medtronic,
Galway, Ireland) in 20, Promus stent (Boston Scientific, Gal-
way, Ireland) in nine, and Xience V stent (Abbott, Tipperary,
Ireland) in four. Multiple stenting was used in 41 (57.7%)
lesions. Among 28 bifurcation lesions, a two-stent strategy
was used in 10 lesions. Intravascular ultrasonography (IVUS)-
guided procedure was performed in five (7.0%) lesions. The
number of stents implanted per lesion was 1.6 0.7, and the
total stent length per lesion was 46.7 22.7 mm. Twenty-six
patients (38.8%) received additional stents to treat non-
rotablated lesions during the index procedure. The total stent
length per patient was 63.6 32.1 mm. Five patients (7.5%)
underwent intra-aortic balloon pump (IABP)-assisted proce-
dures due to cardiogenic shock or intractable ventricular
tachycardia.
The in-hospital and follow-up clinical outcomes are shown
in Table 3. The intervention procedure success rate was 92.5%as five patients died during hospitalization, all of them initially
presenting as cardiogenic shock complicating extensive
myocardial infarction or NSTEMI. The average age for these
five patients was 77.6 9.0 years (range: 62e84). Among
these five, one had triple-vessel disease (TVD), two TVD with
LM bifurcation lesions, one double-vessel disease (DVD) with
LM bifurcation lesion, and the other single-vessel disease.
Three of them had extensive anterior MI and two others
NSTEMI (one following unsuccessful PCI at a local hospital,
while the other one received cardiopulmonary resuscitation at
the emergency department). One TVD patient received RA
plus DES for LM-LAD. One TVD patient received RA plus
DES for LM bifurcation lesion and was finished with a culotte
stenting technique. One TVD patient received RA plus DES
for left circumflex artery (LCX), supplemented with stenting
but no RA for two other vessels. The DVD patient received
RA plus DES for LCX and DES culotte stenting for LM
bifurcation lesion.
Although three NHLBI type B and two type C coronary
dissections occurred during procedure, they were successfully
treated by stenting and not followed by major adverse cardiac
event (MACE). The incidence of out-of-hospital MACE at
a mean follow-up of 23.2 months (range, 5e86) was 17.9%.
Eighteen patients (26.9%) received clinically driven coronary
angiographic follow-up and TLR was needed in seven (10.4%)
patients, all for ischemia, and TVR in seven (10.4%) patients.
All were successfully reopened by PCI and no CABG was
needed. Among patients with angiographic follow-up, no
coronary aneurysms were found in the stented segment.
Probable stent thrombosis occurred in one patient (1.5%) in
the subacute stage with sudden cardiac death 9 days after
the procedure in which a Taxus stent was implanted with
a total length of 40 mm for the LM-LAD/LM-LCX bifurcation
lesion.
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Heavily calcified lesions pose great challenges to PCI, even
in contemporary practices, despite a lot of helpful techniques
and devices. With RA, it is possible to pretreat these lesions,
reducing the vessel rigidity and facilitating subsequent inter-
ventions.14 Although excimer laser is a reasonable alternative,
it is expensive and not available in most cath labs.15 Further-
more, excimer laser is useless in extremely calcified lesions.16
In the BMS era, the combination of RA and BMS was reported
to be most likely associated with optimal final lumen dimen-
sions.17 However, the results of RA plus BMS were not as
good as expected.18 Furthermore, although RA is an effective
and less expensive debulking modality and readily available in
most cath labs, it is more cumbersome to set up, more difficult
to use, especially for distal lesions, and more prone to
complications if not adequately prepared or performed.19,20
Therefore, it has usually been underused, even in the DES
era.21 These limitations were also reflected in our cath labs, in
which rotablation was only used in 2.4% of all PCI cases.
However, lack of insurance reimbursement for rotablation is
probably the major cause of underuse of this device in our
country and many others. Underuse, less familiarity with this
device and resorting to it only in heavily calcified, complex
lesions in high-risk patients may increase the complication
rate and decrease the angiographic and clinical outcomes.
However, these issues were not seen in our cath lab.
DES effectively reduces restenosis and long-term MACE
after PCI; therefore, it prevails in current practice.22 The
angiographic and clinical advantages of DES along with recentTable 4
Summary of large-series reports of RA plus DES.
Author/y Patient
Number
(N )
Age (y) Cr/CRF
(mg/dL)/(N )
(%)
ACS (N ) (%) Number of
diseased
Vessels (N )
CA
sco
Clavijo LC
et al 2006
81 71.5 9.6 1.5 1.8/? 34 (42%) 2.2 0.9 ?
Furuichi S
et al 2009
95 68 9 ?/7 (7.4%) 19 (20%) 1.6 0.8 ?
Tamekiyo H
et al 2009
79 70.6 10.7 ?/34 (43%)a 25 (32%) 1.9 0.7 ?b
Garcı´a de Lara
et al 2010
50 70 1.2 ?/? 30 (60%) 2.4 0.8 ?
Rathore
et al 2010
391 70.8 8.8 ?/?c 52 (13.3%) ?? ?d
Mezilis N
et al 2010
150 70 8 ?/? 14 (8%) ?? ?
Benezet J
et al 2011
102 68.8 7.4 ?/13 (12.7%) 73 (71.6) 2.3 0.7 ?
Chiang MH
et al 2011e
67 73.2 10.3 2.1 2.1/29
(43%)
43 (64%) 2.5 0.6 3.6
1.4
ACS¼ acute coronary syndrome; CAC¼ coronary artery calcification; Cr/CRF = s
up; MACE¼major adverse cardiac event; TLR¼ target lesion revascularization;
? data not available in the original article.
a A total of 43% were dialysis patients.
b A total of 74.2% had severe calcification.
c Patients with advanced renal failure on hemodialysis were excluded in this stu
d Moderate and severe calcification were 161 (41.2%) and 202 (51.7%), respect
e Rotablation not reimbursed by insurance.
f All deaths were due to cardiogenic shock.advancement in other new concepts and techniques encourage
more PCIs for very complex lesions and in high-risk
patients.23 However, the use of DES in heavily calcified
lesions poses special challenges: (1) suboptimal deployment of
DES may increase the risk of stent thrombosis, (2) rigorous
manipulation of a DES may result in disruption of its polymer
coating, and (3) stent delivery failure. CAC might cause
inadequate diffusion of drug to the vessel wall.24 CAC in the
stent delivery route was reported to be an important determi-
nant of restenosis following sirolimus-eluting stent implanta-
tion.10 These calcifications mandate adequate debulking
before standard PCI can be performed. Once the DES is
delivered and deployed, good results can be anticipated.25
Otherwise, DES might fail to prevent restenosis under these
circumstances.26
The coronary calcification score in the current study was
very high. Of our lesions, 26.7% were either balloon-
uncrossable or balloon-undilatable. Our patients were all
high-risk: 64% of patients presented with acute coronary
syndrome, 9.0% with cardiogenic shock, 43.3% with chronic
renal failure, and 50.7% with diabetes. The mean left ventric-
ular ejection fraction (LVEF) was 42% and multiple-vessel
diseases were found in 92.5% of our patients. The final stent
length was 47 23 mm, and the two-stent strategy was used in
36% of true bifurcation lesions in our patients, both demon-
strating the complexity of our treated lesions. Despite all these
unfavorable factors, the angiographic success rate was 100%,
which could be due to more complete lesion modification by
using more than one burr per lesion. Although there were five
(7.4%) in-hospital deaths, none were procedure-related; allC
re
Bailout RA
(N ) (%)
Stent length
per lesion
(mm)
In-hospital
deaths/MACE
(N ) (%)
Mean
FU
FU
MACE/TLR/TVR
(%)
18 (22%) 24.4 6.27 0 (0%)/1 (1.3%) 6 mo 11.0/4.2/??
61 (63.5%) 48.4 24.9 0 (0%)/3 (3.2%) 17.4 mo 15.8/9.5/11.6
? 36.5 17.2 2 (2.5%)/3 (3.8%) 730 d 30.1/25.0/??
? 41 4 2 (4%)/2 (4%) 14 mo 8.0/6.0/??
27 (6.9%) 22.4 12.6 4 (1%)/10 (2.5%) 6e9 mo ?/10.6/?
? 38 10 0 (0%)/0 (0%) 3 y 11.3/2.0/2.0
21 (19.8%) 39.3 19.8 1 (0.9%)/3 (2.9%) 15 mo 12.7/8.8/?
 21 (31%) 46.7 22.7 5 (7.5%)/5 (7.5%)f 23 mo 17.9/10.4/10.4
erum creatinine/chronic renal failure; DES¼ drug-eluting stent; FU = follow-
RA¼ rotational atherectomy; TVR¼ target vessel revascularization.
dy.
ively.
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ischemia with cardiogenic shock. The disease severity in these
five patients was extremely high, as was the PCI complexity
(multi-vessel interventions and two-stent LM bifurcation
interventions). However, RA plus DES could be achieved
without procedural complications. The follow-up MACE in
patients who survived the acute events was 17.9%,most of them
due to TLR and TVR. This figure was quite reasonable given
a group of patients with very complex, heavily calcified coro-
nary lesions. Our study results were comparable with others in
the literature, as summarized in Table 4,25,27e32 despite the
untoward and unfavorable circumstances of using his particular
device in this country.
There were some limitations in our study. The sample size
in this single-center, observational study was relatively small
because of the insurance reimbursement issue in this country.
We had to limit RA use to patients with very unfavorable
angiographic characteristics, which otherwise would preclude
successful PCI treatment without prior mechanical ablation.
Furthermore, there was no routine angiographic follow-up of
these patients. However, clinically driven follow-up, which
was adopted in most DES studies,22 showed the overall MACE
was relatively low and comparable with those of DES treat-
ment in real world practice,22 especially given the unfavorable
background clinical and angiographic settings of our patients.
In conclusion, plaque modification with RA to ensure DES
delivery and appropriate stent deployment in very complex,
heavily calcified lesions appears to be crucial, clinically
rewarding, and could be safely accomplished with very low
complication and low out-of-hospital MACE rates even in
high-risk patients despite use limited by lack of insurance
reimbursement. The high procedural success rate, low TLR
and very pleasing cumulative MACE incidence convince us to
sustain and even broaden use of this novel but underused
device in the DES era.References
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